No Data
No Data
Sana Biotechnology SANA Cell Therapy Data; Vir Biotechnology VIR Phase 1 Data
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%
Vir Biotech Upgraded at Morgan Stanley on Cancer Drug Data
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology Stock
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $14 to $28
QMengColdJoke : After vigorously spending VIR still has 1 billion NET cash. Just say before this jump, This company’s science is literally prices at book value, and science is free… Any buy out is robbery.
Lucky1688 QMengColdJoke : Is this good news or bad news? Little White seeks guidance.